Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC70 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.064 | uM | 10873.145 | 0.9756 | 0.9607 | 1.2454 | |
| HCC70 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.32 | uM | 10873.145 | 0.9648 | 0.9432 | 1.2454 | |
| HCC70 | TNBC | Basal A | Nilotinib | ABL | nRTK | 1.6 | uM | 10873.145 | 1.0538 | 1.0860 | 1.2454 | |
| HCC70 | TNBC | Basal A | Nilotinib | ABL | nRTK | 8 | uM | 10873.145 | 0.9698 | 0.9513 | 1.2454 | |
| HCC70 | TNBC | Basal A | Nilotinib | ABL | nRTK | 40 | uM | 10873.145 | 1.1531 | 1.2423 | 1.2454 | |
| HCC70 | TNBC | Basal A | Nilotinib | ABL | nRTK | 200 | uM | 10873.145 | 1.1098 | 1.1744 | 1.2454 | |
| HCC70 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.000512 | uM | 12400.17 | 0.9971 | 0.9952 | 1.1992 | |
| HCC70 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.00256 | uM | 12400.17 | 0.9468 | 0.9108 | 1.1992 | |
| HCC70 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.0128 | uM | 12400.17 | 1.0476 | 1.0791 | 1.1992 | |
| HCC70 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.064 | uM | 12400.17 | 0.9893 | 0.9822 | 1.1992 | |
| HCC70 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.32 | uM | 12400.17 | 0.9377 | 0.8956 | 1.1992 | |
| HCC70 | TNBC | Basal A | Nilotinib | ABL | nRTK | 1.6 | uM | 12400.17 | 1.0756 | 1.1254 | 1.1992 | |
| HCC70 | TNBC | Basal A | Nilotinib | ABL | nRTK | 8 | uM | 12400.17 | 1.0483 | 1.0803 | 1.1992 | |
| HCC70 | TNBC | Basal A | Nilotinib | ABL | nRTK | 40 | uM | 12400.17 | 1.0800 | 1.1326 | 1.1992 | |
| HCC70 | TNBC | Basal A | Nilotinib | ABL | nRTK | 200 | uM | 12400.17 | 1.0847 | 1.1403 | 1.1992 | |
| Hs 578T | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.000512 | uM | 10694.145 | 0.9871 | 0.9886 | 2.2732 | |
| Hs 578T | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.00256 | uM | 10694.145 | 0.9135 | 0.9220 | 2.2732 | |
| Hs 578T | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.0128 | uM | 10694.145 | 1.0008 | 1.0007 | 2.2732 | |
| Hs 578T | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.064 | uM | 10694.145 | 0.9454 | 0.9512 | 2.2732 | |
| Hs 578T | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.32 | uM | 10694.145 | 1.0103 | 1.0090 | 2.2732 | |
| Hs 578T | TNBC | Basal B | Nilotinib | ABL | nRTK | 1.6 | uM | 10694.145 | 0.8676 | 0.8789 | 2.2732 | |
| Hs 578T | TNBC | Basal B | Nilotinib | ABL | nRTK | 8 | uM | 10694.145 | 0.9368 | 0.9434 | 2.2732 | |
| Hs 578T | TNBC | Basal B | Nilotinib | ABL | nRTK | 40 | uM | 10694.145 | 0.6337 | 0.6363 | 2.2732 | |
| Hs 578T | TNBC | Basal B | Nilotinib | ABL | nRTK | 200 | uM | 10694.145 | 0.7180 | 0.7288 | 2.2732 | |
| LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 10816.145 | 0.9161 | 0.7865 | 0.7766 |